44.30MMarket Cap-469P/E (TTM)
1.900High1.600Low710.45KVolume1.710Open1.760Pre Close1.25MTurnover6.06%Turnover RatioLossP/E (Static)24.89MShares12.88052wk High-0.80P/B20.87MFloat Cap0.78052wk Low--Dividend TTM11.72MShs Float12.880Historical High--Div YieldTTM17.05%Amplitude0.780Historical Low1.766Avg Price1Lot Size
NKGEN BIOTECH Stock Forum
NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on developing and commercializing innovative autologous, allogeneic, and CAR-NK natural killer (“NK”) cell therapeutics, has announced a significant milestone. The company's cryopreserved autologous enhanced SN...
NKGen Biotech, Inc. (Nasdaq: NKGN), a clinical-stage biotechnology company, has announced that its innovative cryopreserved, autologous enhanced natural killer (NK) cell therapy, SNK01, has been cleared to progress into Phase 2 clinical development for the treatment of moderate Alzheimer’s disease. This advanceme...
No comment yet